Abdominal Tuberculosis Diagnosis and Treatment

Patient Presentation and History

The patient presents with progressive abdominal pain, fever, and weight loss over 3-4 months, which are common symptoms of abdominal tuberculosis 1
The patient's history of jaundice, nausea, vomiting, and elevated liver enzymes during prior rifampicin exposure is crucial in determining the treatment regimen 2
The Centers for Disease Control and Prevention recommends a thorough history and physical examination to diagnose abdominal tuberculosis, including assessment of symptoms such as night sweats, anorexia, and low-grade evening fever 1

The American Thoracic Society recommends baseline liver function tests, including ALT, AST, alkaline phosphatase, total and direct bilirubin, albumin, and prothrombin time/INR, to monitor for hepatotoxicity 1
The World Health Organization suggests that ascitic fluid analysis, including cell count, biochemistry, and adenosine deaminase (ADA) levels, can help diagnose tuberculous peritonitis 1
Imaging studies, such as chest X-ray, abdominal ultrasound, and CT abdomen with contrast, are essential in diagnosing abdominal tuberculosis and monitoring treatment response 1

The Infectious Diseases Society of America recommends a 9-month alternative regimen for rifampicin-intolerant patients, consisting of isoniazid, ethambutol, and a fluoroquinolone, with or without pyrazinamide 2
The treatment regimen should be individualized based on the patient's history of hepatotoxicity and drug intolerance, with close monitoring of liver function tests and clinical symptoms 2
The European Respiratory Society suggests that the treatment duration should be extended to 12 months if pyrazinamide is excluded from the regimen 4

The Centers for Disease Control and Prevention recommends weekly monitoring of liver function tests for the first 2 weeks after each drug introduction, followed by monthly monitoring 4
The patient should be educated on symptoms requiring immediate medical attention, such as nausea, vomiting, abdominal pain, and jaundice, and should be advised to avoid hepatotoxic substances 3
The World Health Organization suggests that post-treatment follow-up should include clinical assessment at 3, 6, 12, and 24 months after treatment completion 1